Flunarizine in therapy-resistant infantile epilepsies.
An open add-on trial with flunarizine has been carried out in 27 cases of therapy resistant infantile epilepsies: 15 partial and 12 generalized epilepsies. Etiology was an hypoxic-ischemic encephalopathy (HIE) in 13 cases, cerebral malformations in 10 cases and 4 various prenatal and perinatal cases. After a 2 months baseline period, flunarizine was given in addition to the previous therapy in a 5 mg once daily dose. A single blind versus placebo study was carried out in another series of 16 cases. Better results were found in HIE cases than in malformative cases, and in cases with perinatal HIE than in cases with prenatal hypoxic encephalopathy. The improvement in symptomatic generalized epilepsies was more evident than in symptomatic partial epilepsies. Drowsiness was the only side effect reported.
D000927:Anticonvulsants / Q000627:therapeutic use*; D002675:Child, Preschool; D004311:Double-Blind Method; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005444:Flunarizine / Q000627:therapeutic use*; D006801:Humans; D007223:Infant
D000927:Anticonvulsants; D005444:Flunarizine